Search

BiomX and Adaptive Phage Therapeutics have announced they will merge! They concurrently announce new financing of $50 million, which will help advance the combined company’s two Phase 2 assets: one for CF and one for diabetic foot ulcers.

BiomX, a biotech company developing natural and engineered phages to treat microbiome diseases, announced a merger agreement with Chardan Healthcare Acquisition Corp. The combined company is expected to be listed on the New York Stock Excha

BiomX, a biotech company developing natural and engineered phages to treat microbiome diseases, announced a merger agreement with Chardan Healthcare Acquisition Corp. The combined company is expected to be listed on the New York Stock Excha